Evidence map›Paper›PMID 40338044›Full record

ArticleThe Journal of infectious diseases2025

A Plasma Metabolic Signature to Diagnose Pulmonary Tuberculosis and Monitor Treatment Response.

Jeffrey M Collins, Kidist Bobosha, Naythra Narayanan, Neel R Gandhi, Cheryl L Day, Jyothi Rengarajan, Russell R Kempker, Max S Y Lau, Mary Nellis, Nestani Tukvadze and 13 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Tuberculosis in Pregnancy: Challenges of Immune Protection.The Journal of infectious diseases · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Jeffrey M CollinsDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0002-6574-0873
Kidist BoboshaArmauer Hansen Research Institute, Mycobacterial Diseases Research Directorate, Addis Ababa, Ethiopia.ORCID 0000-0001-8091-7182
Naythra NarayananDepartment of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia, USA.
Neel R GandhiDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Cheryl L DayDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0002-6497-4846
Jyothi RengarajanDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Russell R KempkerDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0002-7188-4996
Max S Y LauDepartment of Biostatistics, Emory University Rollins School of Public Health, Atlanta, Georgia, USA.ORCID 0000-0001-6590-0294
Mary NellisDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Nestani TukvadzeNational Center for Tuberculosis and Lung Disease, Tbilisi, Georgia.ORCID 0000-0002-0276-1204
N Sarita ShahDepartment of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia, USA.
James C M BrustDepartment of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
Azhar NizamDepartment of Biostatistics, Emory University Rollins School of Public Health, Atlanta, Georgia, USA.
Nazir A IsmailDivision of Clinical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.ORCID 0000-0001-7696-3776
Keith D KauffmanT Lymphocyte Biology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Shunsuke SakaiT Lymphocyte Biology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Dean P JonesDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Daniel L BarberT Lymphocyte Biology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Thomas R ZieglerDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Joel D ErnstDivision of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0001-9951-6207
Henry M BlumbergDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Liya WassieArmauer Hansen Research Institute, Mycobacterial Diseases Research Directorate, Addis Ababa, Ethiopia.ORCID 0000-0002-5494-5275
Tuberculosis Research Unit - Role of Antigen-Specific T Cell Responses in the Control of TB (TBRU-ASTRa)

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Role of antigen-specific T cell responses in the control of TBU19AI111211 · NIAID · EMORY UNIVERSITY · PI BLUMBERG, HENRY M · 2014 to 2020
$20.1M
Emory/Georgia TB Research Advancement Center (TRAC)P30AI168386 · NIAID · EMORY UNIVERSITY · PI Neel Rajnikant Gandhi, Jyothi Rengarajan · 2022 to 2026
$5.8M
Emory-Georgia TB Research Training ProgramD43TW007124 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Nestani Tukvadze · 2004 to 2026
$4.6M
Impact of HIV, Antiretroviral Therapy and TB Genotype on Survival in MDR TBR01AI087465 · NIAID · EMORY UNIVERSITY · PI GANDHI, NEEL RAJNIKANT · 2010 to 2014
$3.9M
Immunometabolic Biomarkers to Advance TB Diagnosis and Treatment MonitoringR01AI182244 · NIAID · EMORY UNIVERSITY · PI Jeffrey M Collins · 2024 to 2026
$2.2M
Mentorship in Patient-Oriented Research in Tuberculosis, HIV and Global HealthK24AI114444 · NIAID · EMORY UNIVERSITY · PI GANDHI, NEEL RAJNIKANT · 2014 to 2023
$1.8M
High resolution plasma metabolomics to identify biomarkers of tuberculosisK23AI144040 · NIAID · EMORY UNIVERSITY · PI COLLINS, JEFFREY M · 2019 to 2023
$911k
High-Resolution Plasma Metabolomic Profiling to Identify Biomarkers for Tuberculosis Disease and Response to TherapyR21AI130918 · NIAID · EMORY UNIVERSITY · PI JONES, DEAN PAUL, ZIEGLER, THOMAS R · 2017 to 2018
$442k
FIC NIH HHS D43 TW007124FIC NIH HHS D43TW007124National Institute of Allergy and Infectious Diseases K23AI144040National Institute of Allergy and Infectious Diseases K24AI114444National Institute of Allergy and Infectious Diseases P30AI050409National Institute of Allergy and Infectious Diseases P30AI168386National Institute of Allergy and Infectious Diseases R01AI087465National Institute of Allergy and Infectious Diseases R01AI182244National Institute of Allergy and Infectious Diseases U19AI111211NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1 TR002378NIAID NIH HHS K23 AI144040NIAID NIH HHS K24 AI114444NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI168386NIAID NIH HHS R01 AI087465NIAID NIH HHS R01 AI182244NIAID NIH HHS R21 AI130918NIAID NIH HHS U19 AI111211NIH HHSNIH National Center for Advancing Translational Science UL1TR002378
6 · The paper itself

Abstract

backgroundHigh-resolution metabolomics has shown promise for identifying blood-based biomarkers of tuberculosis (TB). We sought to discover a metabolic signature to detect pulmonary TB disease and monitor treatment response.

methodsPlasma from Ethiopian persons with pulmonary TB at diagnosis (n = 82) was compared to household contacts with TB symptoms (n = 104) and 2, 6, and 12 months after treatment initiation. Participants were divided into training and test sets for model building, with additional validation using independent cohorts from the countries of Georgia (n = 89) and South Africa (n = 85). Signatures were further evaluated in nonhuman primates infected with Mycobacterium tuberculosis (Mtb).

resultsAmong the metabolites that most significantly differed in concentration, tryptophan (Trp) and retinol were significantly decreased in persons with TB disease (45.2 vs 62.5 μM and 4.1 vs 8.2 μM, respectively), while kynurenine (Kyn) was significantly increased (2.1 vs 1.6 μM; q < .0001 for all). A signature that included the Kyn/Trp ratio and retinol showed excellent classification for TB disease (area under the curve [AUC] = 0.97). The signature had an AUC of 0.97 in HIV-positive and 0.95 in HIV-negative persons with TB disease from South Africa and 0.93 in TB patients from Georgia. In Ethiopian participants, signature scores decreased after 2 months (0.85 to 0.42) and 6 months of TB treatment (0.42 to 0.18; P < .0001 for both) to similar levels as controls. Plasma retinol also declined in nonhuman primates infected with Mtb 15-16 weeks after infection (5.9 vs 3.6 μM; P < .001).

conclusionsThe plasma Kyn/Trp ratio and retinol represents a promising metabolic signature that could advance TB diagnostics.

Indexed as

Tuberculosis, PulmonaryAdolescentAdultAnimalsAntitubercular AgentsBiomarkersEthiopiaFemaleHumansKynurenineMaleMetabolomicsMiddle AgedMycobacterium tuberculosisSouth AfricaTreatment OutcomeAntitubercular AgentsBiomarkersKynurenineTryptophanVitamin Abiomarkersdiagnosticsmetabolomicstreatment responsetuberculosis

Identifiers

PMID40338044
PMCPMC12455305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.